Bimekizumab-induced eczematous eruption treated successfully with sequential upadacitinib and dupilumab therapy
Main Article Content
Keywords
General dermatology, Medical dermatology, Immunodermatology, Biologics, Drug response, Clinical research
Abstract
Bimekizumab, a selective IL-17A and IL-17F inhibitor, is FDA-approved for the treatment of adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. While IL-17 inhibitors are generally well tolerated, there have been reports of eczematous eruptions after starting treatment with this medication class. Herein, we report a case of bimekizumab-induced eczematous eruption that partially cleared with upadacitinib (selective oral JAK 1 inhibitor), but ultimately required switching to dupilumab to achieve complete skin clearance.
References
2. Merola JF, Landewé R, McInnes IB, et al. Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE). Lancet. 2023;401(10370):38-48. doi:10.1016/S0140-6736(22)02303-0
3. Al-Janabi A, Foulkes AC, Mason K, Smith CH, Griffiths CEM, Warren RB. Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2020;34(7):1440-1448. doi:10.1111/jdv.16246
4. Gargiulo L, Narcisi A, Ibba L, et al. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study-IL PSO (Italian landscape psoriasis). Front Med (Lausanne). 2023;10:1243843. Published 2023 Aug 8. doi:10.3389/fmed.2023.1243843
5. Blum AE, Burgin S. Eczematous Drug Eruptions. Am J Clin Dermatol. 2021;22(3):349-366. doi:10.1007/s40257-021-00586-8
6. Megna M, Caiazzo G, Parisi M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role?. Clin Exp Dermatol. 2022;47(5):918-925. doi:10.1111/ced.15052
7. Yousif J, Al-Dehneem R, Kaskas N, Gottlieb AB. A Case Series of Patients With Eczematous Eruptions Following IL-17 Inhibitor Treatment for Psoriasis Vulgaris. J Drugs Dermatol. 2023;22(12):1225-1227. doi:10.36849/JDD.7388
8. Guttman-Yassky E, Krueger JG: Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?. Curr Opin Immunol. 2017, 48:68-73. 10.1016/j.coi.2017.08.008
9. Burlando M, Cozzani E, Russo R, Parodi A. Atopic-like dermatitis after secukinumab injection: A case report. Dermatol Ther. 2019;32(1):e12751. doi:10.1111/dth.12751
10. Barry K, Zancanaro P, Casseres R, Dumont N, Rosmarin D. A retrospective review of dupilumab and psoriasis biologic combination therapy. J Dermatolog Treat. 2021;32(4):438-439. doi:10.1080/09546634.2019.1659481
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.